Literature DB >> 23072881

The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy.

Jinhong Chang1, Timothy M Block, Ju-Tao Guo.   

Abstract

Pattern recognition receptor (PRR)-mediated innate immune responses play an essential role in defending the host from viral infections. Intriguingly, hepatitis B virus (HBV) has been shown to induce negligible innate immune responses during the early phase of infection. Whether this is due to the failure of the virus to activate PRRs or suppression of PRR signaling pathways by the virus remains controversial. However, a plethora of evidence suggests that HBV is sensitive to PRR ligand-induced antiviral responses. This review summarizes current understanding of the interaction between HBV and PRR-mediated host innate immunity, antiviral mechanisms of PRR responses against HBV and strategies to combat chronic HBV infection via induction of host innate antiviral responses.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072881     DOI: 10.1016/j.antiviral.2012.10.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  38 in total

1.  An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases.

Authors:  Jieliang Chen; Wen Zhang; Junyu Lin; Fan Wang; Min Wu; Cuncun Chen; Ye Zheng; Xiuhua Peng; Jianhua Li; Zhenghong Yuan
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

2.  Activation of Stimulator of Interferon Genes in Hepatocytes Suppresses the Replication of Hepatitis B Virus.

Authors:  Fang Guo; Liudi Tang; Sainan Shu; Mohit Sehgal; Muhammad Sheraz; Bowei Liu; Qiong Zhao; Junjun Cheng; Xuesen Zhao; Tianlun Zhou; Jinhong Chang; Ju-Tao Guo
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 3.  Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.

Authors:  Jieliang Chen; Zhenghong Yuan
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

4.  Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors.

Authors:  Pinghu Zhang; Fei Liu; Fang Guo; Qiong Zhao; Jinhong Chang; Ju-Tao Guo
Journal:  Antiviral Res       Date:  2016-04-12       Impact factor: 5.970

5.  The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.

Authors:  Ran Yan; Xuesen Zhao; Dawei Cai; Yuanjie Liu; Timothy M Block; Ju-Tao Guo; Haitao Guo
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

6.  Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity.

Authors:  Jianhua Li; Kuancheng Liu; Yang Liu; Yan Xu; Fei Zhang; Huijuan Yang; Jiangxia Liu; Tingting Pan; Jieliang Chen; Min Wu; Xiaohui Zhou; Zhenghong Yuan
Journal:  Nat Immunol       Date:  2013-07-07       Impact factor: 25.606

Review 7.  Chronic hepatitis B: A wave of new therapies on the horizon.

Authors:  Timothy M Block; Siddhartha Rawat; Carol L Brosgart
Journal:  Antiviral Res       Date:  2015-06-22       Impact factor: 5.970

8.  Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.

Authors:  Xuesen Zhao; Mohit Sehgal; Zhifei Hou; Junjun Cheng; Sainan Shu; Shuo Wu; Fang Guo; Sylvain J Le Marchand; Hanxin Lin; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

9.  Viral DNA-Dependent Induction of Innate Immune Response to Hepatitis B Virus in Immortalized Mouse Hepatocytes.

Authors:  Xiuji Cui; Daniel N Clark; Kuancheng Liu; Xiao-Dong Xu; Ju-Tao Guo; Jianming Hu
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

10.  Paediatrics: Children need optimal management of chronic hepatitis B.

Authors:  Mei-Hwei Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-30       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.